Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 7Thyroid Neoplasms 3Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Endocrine Gland Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Adenoma, Islet Cell 1

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × Biopsy, Large-Core Needle × Clear all
NCT01276899 2022-06-02

Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients

Jewish General Hospital

Completed
80 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡